Scpharmaceuticals Stock Alpha and Beta Analysis
SCPH Stock | USD 3.83 0.21 5.20% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Scpharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Scpharmaceuticals over a specified time horizon. Remember, high Scpharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Scpharmaceuticals' market risk premium analysis include:
Beta (0.30) | Alpha (0.43) | Risk 4.05 | Sharpe Ratio (0.13) | Expected Return (0.53) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Scpharmaceuticals |
Scpharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Scpharmaceuticals market risk premium is the additional return an investor will receive from holding Scpharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Scpharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Scpharmaceuticals' performance over market.α | -0.43 | β | -0.3 |
Scpharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Scpharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Scpharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Scpharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Scpharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Scpharmaceuticals shares will generate the highest return on investment. By understating and applying Scpharmaceuticals stock market price indicators, traders can identify Scpharmaceuticals position entry and exit signals to maximize returns.
Scpharmaceuticals Return and Market Media
The median price of Scpharmaceuticals for the period between Thu, Feb 22, 2024 and Wed, May 22, 2024 is 5.02 with a coefficient of variation of 10.56. The daily time series for the period is distributed with a sample standard deviation of 0.54, arithmetic mean of 5.09, and mean deviation of 0.46. The Stock received a lot of media exposure during the period. Price Growth (%) |
Timeline |
1 | Should You Buy Scpharmaceuticals Inc Stock After it Has Gained 7.45 percent in a Week - InvestorsObserver | 02/29/2024 |
2 | scPharmaceuticals Inc. stock most popular amongst private equity firms who own 41, while ... - Yahoo Movies UK | 03/25/2024 |
3 | Acquisition by John Tucker of 56025 shares of Scpharmaceuticals at 7.06 subject to Rule 16b-3 | 03/28/2024 |
4 | Acquisition by Veitinger Klaus R Dr of 16300 shares of Scpharmaceuticals at 4.53 subject to Rule 16b-3 | 04/05/2024 |
5 | scPharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference - The Globe and Mail | 04/09/2024 |
6 | Acquisition by Jack Khattar of 17300 shares of Scpharmaceuticals at 11.71 subject to Rule 16b-3 | 04/16/2024 |
7 | Disposition of 220096 shares by 5am Partners Iv, Llc of Scpharmaceuticals at 5.0 subject to Rule 16b-3 | 04/19/2024 |
8 | scPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study ofFUROSCIX Auto-Injector Injection | 04/24/2024 |
9 | Disposition of 456413 shares by Schwab Andrew J. of Scpharmaceuticals at 4.09 subject to Rule 16b-3 | 04/26/2024 |
10 | SpringWorks Therapeutics Reports Q1 Loss, Tops Revenue Estimates | 05/02/2024 |
11 | scPharmaceuticals to Announce First Quarter 2024 Financial Results onTuesday, May 14, 2024 | 05/07/2024 |
12 | scPharmaceuticals to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference | 05/13/2024 |
13 | scPharmaceuticals GAAP EPS of -0.36 beats by 0.08, revenue of 6.1M beats by 0.12M | 05/14/2024 |
14 | SCPH Stock Earnings scPharmaceuticals Beats EPS, Beats Revenue for Q1 2024 | 05/15/2024 |
About Scpharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Scpharmaceuticals or other stocks. Alpha measures the amount that position in Scpharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
2023 | 2024 (projected) | Payables Turnover | 0.95 | 1.0 | Days Of Inventory On Hand | 846.65 | 1.6K |
Scpharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Scpharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Scpharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Scpharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Scpharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Scpharmaceuticals' management manipulating its earnings.
27th of March 2024 Upcoming Quarterly Report | View | |
8th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
27th of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Scpharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Scpharmaceuticals Backtesting, Scpharmaceuticals Valuation, Scpharmaceuticals Correlation, Scpharmaceuticals Hype Analysis, Scpharmaceuticals Volatility, Scpharmaceuticals History and analyze Scpharmaceuticals Performance. For more detail on how to invest in Scpharmaceuticals Stock please use our How to Invest in Scpharmaceuticals guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Complementary Tools for Scpharmaceuticals Stock analysis
When running Scpharmaceuticals' price analysis, check to measure Scpharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scpharmaceuticals is operating at the current time. Most of Scpharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Scpharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scpharmaceuticals' price. Additionally, you may evaluate how the addition of Scpharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |
Scpharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.